As of Jul 20
| +0.07 / +0.54%|
The 4 analysts offering 12-month price forecasts for Corcept Therapeutics Inc have a median target of 10.50, with a high estimate of 18.00 and a low estimate of 5.00. The median estimate represents a -18.92% decrease from the last price of 12.95.
The current consensus among 4 polled investment analysts is to Buy stock in Corcept Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.